3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Small Cell Lung Carcinoma
10
Carcinoma, Non-Small-Cell Lung
10
Carcinoma, Hepatocellular
8
Lung Neoplasms
6
Colorectal Neoplasms
6
Neoplasms
5
Prostatic Neoplasms
4
Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Solid Tumors
2
Small Cell Lung Cancer Extensive Stage
2
Sarcoma, Alveolar Soft Part
2
Sarcoma
2
Ovarian Neoplasms
2
Mesothelioma, Malignant
2
Melanoma
2
Liver Neoplasms
2
Extensive Stage Lung Small Cell Carcinoma
2
Carcinoma, Renal Cell
2
Carcinoma
2
Wilms Tumor
1
Vulvar Neoplasms
1
Vaccinia
1
Sarcoma, Clear Cell
1
Rhabdomyosarcoma
1
Papillary renal cell carcinoma, sporadic
1
PIK3CA-Mutated Cancers
1
Osteosarcoma
1
Interventions
sofosbuvir-velpatasvir drug combination
1
atezolizumab
1
Specimen Handling
1
Simvastatin
1
Magnetic Resonance Spectroscopy
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Fibrosis
×
atezolizumab
×
30 days
×
Clear all
NCT06096779
2026-06-01
Kirros
Genentech, Inc.
Phase 2
Recruiting
30 enrolled